Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
160 Health InternationalHKSE:02656 -2.87%8 EBITDA Margin % is -13.34% as of Dec. 2025. GuruFocus rates HKSE:02656 with a GF Score™ of 8/100. The stock has 5 warning signs investors should review. Among 119 Medical Distribution companies, 160 Health International ranks worse than 90.76% on this metric.
160 Health International (HKSE:02656) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
160 Health International EBITDA Margin % Related Terms
160 Health International EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02656 vs MCK, COR, CAH: EBITDA Margin % Comparison
For the Medical Distribution subindustry, 160 Health International's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
160 Health International EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, 160 Health International's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where 160 Health International's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
160 Health International (HKSE:02656) has a EBITDA Margin % of -13.34% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on 160 Health International and its competitors. According to the industry distribution chart, 160 Health International ranks #108 out of 119 companies in the Medical Distribution industry, placing it in the top 90.8%.
Is 160 Health International's EBITDA Margin % too high?
160 Health International's current EBITDA Margin % is -13.34%. Based on the distribution chart, 160 Health International ranks #108 out of 119 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, 160 Health International has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does 160 Health International's EBITDA Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, 160 Health International ranks #108 out of 119 companies for EBITDA Margin %. This places 160 Health International in the lower half of its industry. The industry median EBITDA Margin % is 4.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.31, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on 160 Health International and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 160 Health International's current EBITDA Margin % is -13.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 160 Health International stock overvalued right now?
160 Health International (HKSE:02656) has a current EBITDA Margin % of -13.34%. The current EBITDA Margin % is -13.34%. 160 Health International's overall GF Score™ is 8/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For 160 Health International (HKSE:02656), the current EBITDA Margin % is -13.34% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
160 Health International Ltd is an experienced pharmaceutical and healthcare product wholesaler and a digital healthcare integrated service provider in China. The company offers a wide assortment of high-quality pharmaceutical and healthcare products under both wholesale and retail models, to address a spectrum of customer needs. In addition, through its online healthcare and wellness service platform, Healthcare 160 Platform. It also provide digital healthcare and wellness solutions, empowering each Platform Participants, including business customers, medical and healthcare institutions, medical professionals, individual users, and third-party merchants, throughout the healthcare value chain and driving the digital transformation of China's healthcare and wellness industry.
8GF Score
Get the complete analysis for HKSE:02656
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02656 has been successfully added to your 
